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Abstract
The mammalian prostate arises from the urogenital sinus and few factors have been identified to be important in the early stages of prostate
development. In this study we show that the transcription factor Sox9 is expressed in the epithelia of all mouse prostatic lobes from the initial
stages of their development. We used a conditional approach with mice expressing Cre recombinase under the control of Nkx3.1 regulatory
sequences to delete Sox9 from the developing prostate. Mice with a prostate specific deletion of Sox9 showed a lack of ventral prostate
development and abnormal anterior prostate differentiation. Analysis of these mutant animals revealed an early loss of expression of genes specific
to the prostate epithelia such as Nkx3.1 and Shh and a marked reduction in proliferation in the ventral prostate but not in other lobes. Fgf
signalling, through the MAPK pathway, has been shown to be important in prostate development and a lobe specific phenotype was reported for a
prostate specific Fgfr2 mutant mouse model. Here we show that the levels of Fgfr2 and Sprouty2, a downstream target of Fgf signalling, were
severely reduced in the ventral prostate of Sox9 mutant animals but not in other lobes. Prostate organ culture studies with a Mek inhibitor, U0126,
and a Fgf receptor inhibitor, SU5402, indicate that the timing of expression of Cre in the mutant animals could account for the lobe specific
phenotype in the Sox9 and Fgfr2 mutants. These studies imply that Sox9 is required for the early differentiation of the prostate bud epithelia.
© 2008 Elsevier Inc. All rights reserved.Keywords: Prostate development; Sox9; Fgf signallingIntroduction
The mammalian prostate develops from the urogenital sinus
under the influence of androgens produced by the embryonic
testis (Cunha et al., 1987). Studies in mice have shown that
androgens act on the androgen receptor present in the urogenital
sinus mesenchyme, which then signals the epithelia to initiate
prostate bud formation (Cunha and Chung, 1981; Cunha and
Lung, 1978). Epithelial buds first appear around embryonic day
17.5 (E17.5) in the mouse and grow out into the surrounding
mesenchyme. This growth is followed by extensive branching,
canalization and differentiation into luminal secretory cells and
basal cells. The surrounding mesenchymal cells differentiate
into smooth muscle and fibroblasts, which interact with the
epithelia to form a fully differentiated organ.
The mouse prostate grows into several distinct bilaterally
symmetrical lobes that are named anterior, dorsal, lateral and⁎ Corresponding author. Fax: +44 207 1535514.
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doi:10.1016/j.ydbio.2008.01.030ventral. Each type of lobe has a defined structure and branching
pattern, which is specific, and has a different secretory protein
profile (Sugimura et al., 1986a). The molecular pathways that
control this specificity are currently unknown but it is thought
that regional differences within the mesenchyme are responsible
for inducing lobe identity (Cunha et al., 1992). The structure of
the human prostate is more compact and lacks distinct lobes but
has been described as having three different zones: central,
transitional and peripheral (McNeal, 1981). Despite the
difference in adult structures, morphogenesis is thought to
occur in an analogous manner between human and rodents
(Cunha et al., 1987; Price, 1963).
Several signalling pathways have been identified to be
important in the early development of the prostate. The
signalling molecule fibroblast growth factor 10 (Fgf10) has
been shown to be expressed in the mesenchyme of the
urogenital sinus and mice lacking this factor developed prostate
bud rudiments that then failed to grow (Donjacour et al., 2003;
Thomson and Cunha, 1999). Addition of Fgf10 to prostate
epithelia, separated from nearby mesenchyme, induced
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this factor in prostate development (Huang et al., 2005). Fgf10
is thought to bind to the receptor Fgfr2, which has been shown
to be expressed in the developing prostate epithelia (Huang et
al., 2005). Consistent with this, Fgfr2 mutant mice have defects
in prostate development (Lin et al., 2007).
Factors that have been implicated in prostate development
have also been associated with malignancies such as prostate
cancer. The transcription factor Nkx3.1 is expressed in the
epithelia of the early prostatic buds as they form and mice that
lack this gene showed defects in ductal morphology accom-
panied by hyperplasia and dysplasia in the adult organ (Bhatia-
Gaur et al., 1999). Studies in mice and humans have associated
loss of Nkx3.1 with the initiation events that give rise to prostate
cancer (Shen and Abate-Shen, 2003). Similarly, the signalling
molecule Sonic hedgehog (Shh) has been shown to be
expressed in the early prostatic buds and inhibition of this
pathway led to defects in gland morphogenesis (Berman et al.,
2004; Freestone et al., 2003; Podlasek et al., 1999; Wang et al.,
2003). Aberrant hedgehog signalling pathway has been
associated with metastatic prostate cancer in humans (Karhad-
kar et al., 2004).
Sox9 is a transcription factor that belongs to the SoxE gene
family, which consists of three members (Sox8, Sox9 and
Sox10). This family is required for many processes during
development including testis development, chondrogenesis and
neural crest differentiation (Bi et al., 1999; Cheung et al., 2005;
Kobayashi et al., 2005). In these processes, Sox9 was found to
be expressed at the early stages of tissue development and has
been shown to be required for the initial steps of cell
differentiation. In this paper we describe a novel role for this
factor in the early development of the prostate. We show that
high levels of Sox9 expression were associated with the prostate
epithelia as it forms. Due to the perinatal lethality of the
heterozygous Sox9mutant mice we used a conditional approach
to delete Sox9 in the prostate (Bi et al., 2001). Mice that lack
this gene within the embryonic prostate showed a failure of
ventral prostate development. In depth analysis of this
phenotype showed that Sox9 was required for the expression
of genes associated with the early prostate epithelia in the
developing ventral prostate. This indicated that this factor was
required for prostate bud differentiation during the early stages
of development.
Materials and methods
Mouse strains
The mice containing the Sox9 conditional allele was kindly provided by
Andreas Schedl (INSERM U470, Nice, France) (Akiyama et al., 2002). The
Nkx3.1:Cre allele was created by introducing the Cre gene by homologous
recombination into the Nkx3.1 locus (Lin et al., 2007; Y.-P. Hu, S. M. Price, Z.
Chen, W. Banach-Petrosky, C. Abate-Shen, and M. M. S., manuscript in
preparation). Cre expression was observed in the developing prostate as
described in the Results section and in some areas around the spinal cord of
E13.5 embryos. No expression was observed in the developing testis in these
mice (data not shown). These animals were bred on a mixed genetic background.
We define midday of the day of plug as E0.5 and most pregnant females in this
study gave birth on E19.Organ culture system
Urogenital sinuses were dissected from embryos of different stages and grown
on Biopore membranes (MilliPore) with culture media (DMEM/F-12 HAM 1/1
mixture) supplemented with ITS+1 (Sigma-Aldrich I-2521) at 20 μl/ml,
gentamicin (0.05 mg/ml), benzylpenicillin sodium (0.12 mg/ml), streptomycin
sulphate (0.2 mg/ml), ampicillin (0.1mg/ml) and 10−8M dihydrotestosterone. The
Mek inhibitor U0126 was added the media at a concentration of 20 μM
(Calbiochem). The Fgf receptor inhibitor SU5402 was added to the media at a
concentration of 5 μm (Calbiochem).
Kidney capsule grafts
Urogenital sinuses were taken from E15.5 or E18.5 embryos and grown for
1 day in organ culture. Cultures of the appropriate genetic background were
placed under the kidney capsule of male nude mice as described previously and
grown for 4 weeks (Cunha and Donjacour, 1987; Doles et al., 2005).
Experiments were performed with tissue from at least three independent mutant
and control samples.
Whole mount in situ hybridisation (WISH)
WISHwere carried out on an in situ processor (Intavis In Situ Pro) according
to standard protocols (Val et al., 2006). Probes for Sox9, and Nkx3.1 have been
described previously (Bhatia-Gaur et al., 1999; Swain et al., 1998). The Fgfr2,
Sprouty2 and ShhDIG containing probes were synthesized from PCR fragments
containing T7 RNA polymerase promoter sequences as described previously
(Val et al., 2006). These fragments were derived from the amplification of mouse
cDNA or genomic DNA using the following primers:
Fgfr2: 5′CGCAGGATGGACCTCTCTAC3′ and
5′GTAATACGACTCACTATAGGGCGACCAACTGCTTGAATGTG3′;
Shh: 5′GACAGCTCACAAGTCCTCAG3′and
5′GTAATACGACTCACTATAGGGACGTAAGTCCTTCACCA3′;
Sprouty2: 5′CATGAAAGACTCCACGGTCT3′ and
5′GTAATACGACTCACTATAGGGCCTGTTCACTCGGTCATAAC3′.
Immunohistochemistry
Antibody stains were done on paraffin sections. Tissues were fixed
overnight in 4% paraformaldehyde (PFA), dehydrated by washing through an
ethanol gradient series, washed in histoclear and embedded in wax. 4 μm
sections were cut, treated with histoclear and rehydrated through an ethanol
gradient series. Antigen retrieval was obtained by boiling the sections in citrate
buffer (0.1 M sodium citrate pH6 and 0.05% Tween) and sections were treated
with 0.3% H2O2 to block endogenous peroxidase activity. Sections were
incubated in PBS with 10% sheep serum and then incubated with primary and
secondary antibodies in PBS with 1% sheep serum. Sections were counter-
stained with hematoxylin. Two Sox9 antibodies were used, which gave similar
results. One was a kind gift from Robin Lovell-Badge (NIMR, London, UK) and
used at a 1/16000 dilution and the other was a kind gift from Francis Poulat
(CNRS, Montpellier, France) and used at a 1/2000 dilution. The p63 antibody
(4A4, Santa Cruz Biotechnology) was used at a 1/200 dilution. The cytokeratin
18 antibody (65028, Progen) was used undiluted. For DAB chromogen staining
the ABC vector kit was used (Vector Laboratories) according to manufacturer's
instructions. Secondary fluorescent antibodies were obtained from Molecular
Probes and were used at a 1/1000 dilution. Western blotting was performed
using standard protocols. The ppERK antibody (MAPK-YT, Sigma-Aldrich)
was used at a 1/10,000 dilution and the ERK antibody (C-14, Santa Cruz
Biotechnology) was used at a 1/3000 dilution.
Apoptosis and proliferation
Apoptosis was detected by TUNEL assays according to manufacturer's
instructions (Roche). For proliferation analysis, pregnant mice were injected
with bromodeoxyuridine at 50 mg/kg 2 h before embryo dissection. Tissues
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addition of an extra step of antigen retrieval by incubating in 2N HCL at 37C.
The acid was neutralised by washes in 0.1 M sodium borate pH8.5 and the
sections were then incubated with primary anti-BrdU antibody (clone BMC9318,
Roche) at a dilution of 1/50. Cells were counted on a Leica fluorescence
microscope and prostate buds were identified by differential interference contrast
microscopy.
β-Galactosidase staining
Tissues were dissected and fixed in PBS with 2% PFA and 0.1%
glutaraldehyde for 30 min. After extensive washing in PBS, tissues were
stained at 37C in staining buffer (1 mg/ml X-gal, 2 mM MgCl2, 5 mM K3Fe
(CN)6, 5 mMK4Fe(CN)6 and 0.02% NP-40 in PBS). For sections, after staining,
tissues were processed for paraffin sections as described above and counter-
stained with nuclear fast red.Results
Sox9 expression is associated with early prostate bud epithelia
development
In an investigation using whole mount in situ hybridisation
(WISH) to identify genes expressed in the neonatal mouse
prostate, we found that expression of Sox9 was specifically
upregulated in prostate epithelia. WISH on mouse urogenital
sinuses at various stages showed that Sox9 was expressed at low
levels in the urogenital sinus epithelia in both XX and XY
embryos and was then strongly upregulated in the prostatic buds
as they formed in the male (Fig. 1). High Sox9 expression was
first observed at E17.5 and was then associated with the
prostatic buds as they grew (Fig. 1A). Expression of Sox9 was
also associated with the developing seminal vesicles (Fig. 1A).
Antibody staining confirmed that Sox9 was confined to the
nuclei of prostate epithelia cells and showed that expression was
highest at the tips of the growing buds (Fig. 1B).Fig. 1. Sox9 is expressed in the developing prostate epithelial buds. (A) WISH of diss
of different stages as indicated. The positions of the different lobes in the XYembryo
dorso-lateral prostate; SV: seminal vesicles. (B) Sox9 antibody stain on a section o
magnification (100×) of the boxed region in the top panel.Sox9 is required for ventral prostate development
To investigate the role of Sox9 in prostate development, we
used mice with a conditional allele of Sox9 and mice where Cre
recombinase had been inserted into the Nkx3.1 locus by
homologous recombination (Nkx3.1:Cre mice) (Lin et al.,
2007; Wang et al., 2006). To determine the expression of active
Cre in the Nkx3.1:Cre mice during prostate development we
mated these mice to the Rosa26 reporter strain of mice,
which shows activation of LacZ expression in tissues where
Cre-mediated DNA recombination has taken place (Soriano,
1999). As shown in Fig. 2A, LacZ expression in the
urogenital sinus was first seen around E17.5 in the anterior
prostate and was restricted to the epithelia of the prostate. At
later stages, all epithelial cells of the developing prostate were
positive for LacZ expression. Prostate development was found
to be normal in these mice.
Prostates of mice that were heterozygous for the Sox9
conditional allele and the Nkx3.1:Cre allele (Sox9fl/+; Nkx3.1:
CreCre/+, referred to as Sox9 heterozygous mice) developed
normally. However, a few of these mice showed bone
malformations, which was probably due to expression of Cre
in the embryonic intermediate mesoderm (Y.-P. Hu, S. M. Price,
Z. Chen, W. Banach-Petrosky, C. Abate-Shen, and M. M. S.,
manuscript in preparation) and is consistent with the role of
Sox9 in chondrogenesis (Bi et al., 2001) (data not shown).
Mice that were homozygous for the Sox9 conditional allele
and heterozygous for the Nkx3.1:Cre allele (Sox9fl/fl; Nkx3.1:
CreCre/+ mice, referred to as Sox9 mutant mice) died
perinatally. Using an antibody to Sox9, we determined that
very few cells in the anterior and ventral prostate lobes lacked
this protein at E17.5 in the Sox9 mutant mice (Fig. 2B).
However, at E18.5, most of the epithelial cells of the anterior
(more than 99%) and ventral (more than 95%) prostate in theected urogenital sinuses from XY (top panels) and XX (bottom panels) embryos
s are indicated by arrowheads. AP: anterior prostate; VP: ventral prostate; DLP:
f the urogenital sinus of an E17.5 male embryo. The bottom panel is a higher
Fig. 2. Analysis of Cre activity and Sox9 protein in Sox9 mutant mice. (A) β-Galactosidase stain on dissected urogenital sinuses from male embryos that were
heterozygous for the Nkx3.1:Cre allele and the Rosa26LacZ reporter allele (Rosa26LacZ/+; Nkx3.1:CreCre/+). The stage of the embryo and the different lobes are
indicated. The right panel shows a section of the stained sample in the middle panel in the orientation indicated by the dotted line. (B) Sections of urogenital sinuses
from E17.5 and E18.5 male embryos stained with a Sox9 antibody (brown) as indicated. Embryos were heterozygous for the Nkx3.1:Cre allele and either heterozygous
(HET=Sox9fl/+; Nkx3.1:CreCre/+) or homozygous for the Sox9 conditional allele (MUT=Sox9fl/fl; Nkx3.1:CreCre/+). Smaller panels at the right show a higher
magnification (40×) of the different lobes as indicated. AP: anterior prostate; VP: ventral prostate; DLP: dorso-lateral prostate.
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samples showed this phenotype) (Fig. 2B). The dorso-lateral
buds still showed Sox9 positive cells at this stage (Supple-
mentary Figure S1). At later stages, Sox9 was found to be
absent from all prostatic buds. These studies show that
substantial deletion of Sox9 occurred after E17.5 in the Sox9
mutant mice.
Because the Sox9 mutant mice died at birth, we grew
urogenital sinuses from E15.5 embryos under kidney capsules
of adult male mice to analyse the prostate phenotype in these
mutant mice. Initial analysis of these tissues after 4 weeks of
growth revealed the absence of structures characteristic of the
ventral prostate although other lobes were present (data not
shown). To further investigate this phenotype we dissected the
anterior, dorso-lateral and ventral lobes of E18.5 prostates and
grew them individually under the kidney capsule of male mice
for 4 weeks (Fig. 3A). Analysis of these tissues revealed a
severe defect in the development of the ventral prostate of Sox9
mutant tissues when compared to control samples (Sox9
heterozygous mice or mice lacking the Nkx3.1:Cre allele)(Fig. 3B). The tissues from the Sox9 mutant samples were
significantly smaller, and sections of these samples revealed
very little recognizable prostate structure (40.3±9.8 mg versus
228.5±54.5 mg; three out of three mutant samples showed this
phenotype) (Fig. 3C). Although Sox9 mutant samples derived
from the anterior prostate did grow, three out of five samples
showed a lack of structure characteristic of the anterior prostate
(Fig. 3C panels b). Analysis on these samples using antibodies
to p63, which is found in basal cells, and cytokeratin 18, which
is found in luminal cells, showed that prostatic differentiation
had taken place in these samples but that the lumens of the ducts
were filled with cytokeratin 18 positive cells (Fig. 3D). The
samples derived dorso-lateral prostate showed normal devel-
opment when compared to control samples (Fig. 3C).
To determine the stage of appearance of this phenotype we
grew dissected lobes from E18.5 prostates in organ culture.
After 4 days in culture, the tissues were processed for WISH.
Analysis of Nkx3.1 expression showed that the anterior and
dorso-lateral prostates had developed in the Sox9 mutant tissue
when compared to control samples (Sox9 heterozygous mice or
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or Nkx3.1 expression were observed in the ventral prostates of
Sox9 mutant mice (six out of six mutant and heterozygous
samples showed this phenotype) (Fig. 4A). Although the
Nkx3.1:Cre allele inactivated the Nkx3.1 locus we did not find
any phenotypic difference between our control samples (Sox9
heterozygous mice compared to mice lacking the Nkx3.1:Cre
allele) in any of our experiments. By including the Rosa26
reporter strain in our breeding programme, we were able tostudy the fate of cells that had expressed or were expressing Cre
and were therefore most likely lacking Sox9. These studies
identified LacZ positive tissue in the ventral prostate region of
Sox9 mutant prostates that had been grown as organ cultures
(Fig. 4B). However, this tissue did not express Nkx3.1 or other
genes expressed in the developing prostate epithelia such as Shh
(Fig. 4 and data not shown).
Reduced proliferation in the ventral prostate of Sox9 mutant
mice
We next investigated whether the lack of ventral prostate
development in Sox9 mutant mice was due to an increase in
apoptosis or a decrease in proliferation. Apoptosis was analysed
by TUNEL assay and no difference was observed between Sox9
mutant and control prostates (data not shown). Using
bromodeoxyuridine (BrdU) incorporation, antibody analysis
revealed that there were about two-fold fewer proliferating cells
in the prostate epithelia of the ventral lobe of Sox9 mutant
animals at E18.5 compared to control mice (four mutant and
four control samples were analysed) (Fig. 5). No difference in
BrdU staining was observed between control and mutant mice
in the anterior lobe at this stage.
Early loss of prostate epithelial markers in the ventral prostate
of Sox9 mutant mice
To characterise the early prostate phenotype in the Sox9
mutant mice we performed WISH on prostates from E18.5
embryos. These studies revealed that expression of genes that
were expressed in the early prostate bud epithelia such as
Nkx3.1 and Shh was severely downregulated in the ventral
prostate of mutant Sox9 mice compared to control animals at
this early stage (Fig. 6A). However, no noticeable difference in
expression was observed in the other prostate lobes. Analysis of
Nkx3.1 expression on prostates from E17.5 embryos showed
that at this early stage this gene was present in all Sox9 mutant
prostatic lobes (Supplementary Figure S2A). This is consistent
with our Sox9 antibody analysis showing that E18.5 is when
Sox9 protein is first seen to substantially disappear from theFig. 3. Ventral prostate development is severely affected in Sox9 mutant mice.
(A) Schematic on a dissected E18.5 male urogenital sinus from an animal that
was heterozygous for the Nkx3.1:Cre allele and the Rosa26LacZ reporter allele
stained for β-galactosidase to indicate the lobe specific regions that were
dissected before growth under kidney capsules. (B) Brightfield picture of
ventral prostates from E18.5 male embryos grown for 1 month under the kidney
capsule of male mice. (C) Sections stained with hematoxylin and eosin from
prostates grown for 1 month under the kidney capsule of male mice. Higher
magnification (40×) pictures are shown in the top right hand corner of each
panel. The two sections shown for the mutant anterior prostate reflect the two
different phenotypes observed (a and b). (D) Staining with p63 and cytokeratin
18 (CK18) antibodies (brown stain) of anterior prostate samples grown under
the kidney capsule of male mice. The Sox9 mutant sample that developed
abnormally (panel b in section C) was selected for staining. Embryos were
heterozygous for the Nkx3.1:Cre allele and either heterozygous (HET=Sox9fl/+;
Nkx3.1:CreCre/+) or homozygous for the Sox9 conditional allele (MUT=Sox9fl/fl;
Nkx3.1:CreCre/+). AP: anterior prostate; VP: ventral prostate; DLP: dorso-lateral
prostate.
Fig. 4. Ventral prostate defect in Sox9 mutant mice occurs at early stages. (A)
WISH for Nkx3.1 expression on lobe-specific organ culture samples from E18.5
male embryos that have been grown for 4 days. Embryos were heterozygous for
the Nkx3.1:Cre allele and either heterozygous (HET=Sox9fl/+; Nkx3.1:CreCre/+)
or homozygous for the Sox9 conditional allele (MUT=Sox9fl/fl; Nkx3.1:CreCre/+).
(B) β-Galactosidase stain on ventral prostate organ culture samples from E18.5
male embryos with the Rosa26LacZ reporter allele that have been grown for
4 days. Embryos were heterozygous for the Nkx3.1:Cre allele and either
heterozygous (HET=Rosa26LacZ/+; Sox9fl/+; Nkx3.1:CreCre/+) or homozygous
for the Sox9 conditional allele (MUT=Rosa26LacZ/+; Sox9fl/fl; Nkx3.1:CreCre/+).
AP: anterior prostate; VP: ventral prostate; DLP: dorso-lateral prostate.
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early response to the lack of this factor. Analysis of LacZ
expression in mice that also contained the Rosa26 reporter allele
revealed the presence of LacZ positive tissue in this region
albeit of a smaller size (Supplementary Figure S2B). The
presence of bud like structures was confirmed in the antibody
analysis of sections from Sox9 mutant mice (see Fig. 2B) and
shows that the absence of expression of these genes in the
mutant ventral prostate is not due to the absence of tissue.
A recent study by Lin et al. (2007) showed that mice carrying
a conditional allele of Fgfr2 and the Nkx3.1:Cre allele failed to
develop anterior and ventral prostates but had relatively normal
dorsal and lateral prostate development. Fgfr2 is expressed in
the prostate epithelia as it forms, therefore we analysed the
expression of this gene in Sox9 mutant animals and found that,
as in the case of other genes expressed in the developing
prostate, expression was severely downregulated in the ventralprostate but not in other lobes (Fig. 6B). A similar pattern was
observed for Sprouty2 expression, which has been shown to be
dependent on Fgf signalling (Mason et al., 2006) (Fig. 6B).
Inhibition of MAPK pathway leads to lobe specific phenotypes
in the prostate
Fgfr2 and Sox9 are expressed in all prostatic lobes during
development, however, lack of either of these genes showed a
lobe specific phenotype. Both mutant animals carry the Nkx3.1:
Cre allele, therefore we wanted to determine whether the timing
of appearance of active Cre recombinase during prostate bud
development could account for the lobe specific phenotype.
Fgfr2 has been shown to signal through the mitogen-activated
protein kinase (MAPK) pathway in the prostate (Huang et al.,
2005; Kuslak and Marker, 2007; Pu et al., 2007). To investigate
whether the timing of Fgf signalling disruption had an effect on
the resulting prostate phenotype, we grew prostates from wild
type embryos of different stages in organ cultures for 4 days in
the presence of the MAPK kinase (Mek) inhibitor U0126. To
determine the presence of bud formation, we performed WISH
on organ culture samples for Sox9 expression. These experi-
ments showed that development of all prostatic lobes from
E16.5 embryos was severely delayed in the presence of the
inhibitor when compared to control samples (six out of six
samples treated samples showed this phenotype) (Fig. 7B).
However, bud elongation and growth was observed in cultures
of prostates from E18.5 embryos grown with the inhibitor (six
out of six treated samples showed this phenotype) (Fig. 7 shows
the results for the anterior and ventral prostate dissected as in the
panel in A). Interestingly, E17.5 embryos showed a lobe
specific phenotype with bud elongation and growth only seen in
the anterior lobes (9 out of 10 treated samples showed this
phenotype) (Fig. 7B). A similar result was seen when the
expression of Nkx3.1 was investigated (Fig. 7C). The efficiency
of inhibition by U0126 was controlled by western blotting for
the presence of diphospho extracellular-signal regulated kinase
(ppERK) (Fig. 7D). To confirm that the phenotype observed
with the Mek inhibitor, U0126, was mainly due to a defect in
Fgf signalling we performed similar studies with the Fgf
receptor inhibitor, SU5402, which revealed an identical
phenotype (six out of six treated samples for each time point
showed this phenotype) (Fig. 7B).
Discussion
Our expression analysis revealed that high expression of
Sox9 was associated with the epithelia of the prostate as it
develops. This expression pattern was similar to that of Nkx3.1
and was found to be highest at the tips of the emerging prostatic
buds. The tips of the elongating buds have been shown to be
areas of increased proliferation and branching activity in the
developing prostate suggesting an important role for Sox9 in the
early growth of this organ (Sugimura et al., 1986b). Embryos
that are heterozygous for a deletion of Sox9 die perinatally,
therefore a tissue specific conditional approach was needed to
analyse the role of this gene in prostate development. Our
Fig. 5. Reduced proliferation in the ventral prostate of E18.5 Sox9 mutant mice. (A) BrdU antibody stain on sections of urogenital sinuses from E18.5 male embryos
that were heterozygous for the Nkx3.1:Cre allele and either heterozygous (HET=Sox9fl/+; Nkx3.1:CreCre/+) or homozygous for the Sox9 conditional allele
(MUT=Sox9fl/fl; Nkx3.1:CreCre/+). The anterior (AP) and ventral (VP) buds are outlined by a dashed white line. (B) The mean percentage of BrdU positive cells in the
Sox9 mutant ventral prostate is two-fold lower than the heterozygous Sox9 ventral prostate. Cells from the anterior and ventral prostate of four samples from each
genotype were counted. *Pb0.05 in Student's t-test.
308 M.K. Thomsen et al. / Developmental Biology 316 (2008) 302–311studies demonstrate that Sox9 is required for the formation of
the ventral prostate. Expression analysis showed a severe
downregulation of genes that are specific to the early ventral
bud epithelia very soon after the disappearance of Sox9 protein.
Our analysis of mice containing the Rosa26 reporter allele
showed that tissue where Cre had been expressed was still
present in the mutant embryos, although this tissue had ceased
to express genes such as Shh and Nkx3.1. The expression ofFig. 6. Nkx3.1 Shh, Fgfr2 and Sprouty2 expression are downregulated in the ventral p
Fgfr2 and Sprouty2 (B) expression on dissected urogenital sinuses from E18.5 male e
(HET=Sox9fl/+; Nkx3.1:CreCre/+) or homozygous for the Sox9 conditional allele (MU
arrowheads, the ventral prostate region is circled. AP: anterior prostate; VP: ventralcytokeratin 18, which is found at high levels in luminal cells
that form at late stages of epithelial differentiation, was
investigated and also found not to be upregulated in the mutant
ventral prostate (data not shown). This suggests that lack of
Sox9 led to a loss of prostate bud differentiation at the early
stages of development.
Our reporter studies on the Nkx3.1:Cre allele and the Sox9
antibody analysis on mutant samples showed that deletion ofrostate of E18.5 Sox9mutant mice. (A and B) WISH for Nkx3.1 and Shh (A) and
mbryos that were heterozygous for the Nkx3.1:Cre allele and either heterozygous
T=Sox9fl/fl; Nkx3.1:CreCre/+) as indicated. The different lobes are indicated by
prostate; DLP: dorso-lateral prostate.
Fig. 7. Phenotype of urogenital sinuses in organ cultures treated with the Mek
inhibitor U0126 and the Fgf receptor inhibitor SU5402. (A) Schematic on a
dissected E18.5 male urogenital sinus from an animal that was heterozygous
for the Nkx3.1:Cre allele and the Rosa26LacZ reporter allele stained for
β-galactosidase to indicate the regions that were dissected from E17.5 and E18.5
embryos before organ culture growth. For E16.5 embryos, the region where the
prostate forms from the urogenital sinus was dissected. (B) WISH for Sox9
expression on urogenital sinuses of male embryos of different stages either
untreated or grown with U0126 or SU5402 for 4 days. The different stages and
lobes are indicated. AP: anterior prostate; VP: ventral prostate. (C) WISH for
Nkx3.1 expression on urogenital sinuses of male embryos of different stages
either untreated or grown with U0126 for 4 days. The different stages and lobes
are indicated with arrowheads. AP: anterior prostate; VP: ventral prostate. (D)
Western blot on proteins derived from dissected urogenital sinuses grown with
U0126 for 4 days using an antibody to diphospho extracellular-signal regulated
kinase (ppErk). An antibody to extracellular-signal regulated kinase (Erk) was
used as a loading control.
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Sox9 expression. Therefore we were not able to address the
question of the role of Sox9 in the induction of prostatic buds
from the urogenital sinus epithelium with these mice. Never-
theless, this study shows that Sox9 has a role in the development
of the anterior and ventral buds. Our data show that after the
initial induction of prostate bud development, the lack of Sox9
led to a loss of differentiation and bud elongation and a
reduction in proliferation within the ventral buds. The anterior
buds did initially develop in these mutant mice but subsequent
differentiation was abnormal. Consistent with the lack of an
early prostate phenotype in the Nkx3.1 mutant mice, we have
not seen a difference in prostate development, at the stages
analysed, between the wild type embryos and embryos that are
heterozygous for the Nkx3.1:Cre allele (Bhatia-Gaur et al.,
1999). However, in this mouse model we cannot exclude the
possibility that haploinsufficiency for Nkx3.1 is required for the
phenotype observed in the Sox9 mutant animals.
The similar lobe specific phenotype between Sox9 and Fgfr2
mutant mice suggests that these genes act in the same pathway
during early prostate development. Interaction between Fgf
signalling and Sox9 has been shown for other developmental
processes such as testis development and chondrogenesis. In
both cases, Fgf signalling, through the MAPK pathway, has
been shown to activate Sox9 expression (Murakami et al., 2000;
Schmahl et al., 2004). However, our study with the Mek and Fgf
receptor inhibitors showed that maintenance of Sox9 expression
in the prostate epithelia does not require active Fgf signalling.
Analysis of Fgfr2 mutant mice showed that this receptor is
required for ventral prostate development, therefore the ventral
prostate phenotype in Sox9 mutant animals could be explained
by the loss of Fgfr2 expression in this lobe. This is consistent
with experiments with inhibitors of Mek and Fgf receptor
activation by us and others, which suggest that inhibition of Fgf
signalling or the MAPK pathway at early stages interferes with
prostate bud growth and differentiation (Kuslak and Marker,
2007). However, the presence of Fgfr2 within the anterior
prostate of the Sox9 mutant animals suggests that the regulation
of Fgfr2 expression by Sox9 is dependent on the context.
Therefore the data presented in this study suggest that these
factors act in parallel pathways that interconnect to determine
early prostate bud development.
Our organ culture studies with the Mek and Fgf receptor
inhibitors show that there are two phases to the development of
the prostatic buds. In the first phase, as shown by the E16.5
cultures, after the initiation of prostate bud development, the
subsequent elongation and growth are dependent on Fgf
signalling. However, in the second phase, as shown by the
E18.5 cultures, elongation and growth are independent of Fgf
signalling. These two phases could reflect the different stages of
bud development where the buds first emerge from the
urogenital sinus epithelia and grow through the peri-urethral
mesenchyme to reach the dense mesenchymal zones, such as
the ventral mesenchymal pad (VMP) seen in the rat, where they
undergo branching morphogenesis (Cunha et al., 2004). Fgf10
has been shown to be important in early bud formation and its
expression is confined to the mesenchyme distal to the
310 M.K. Thomsen et al. / Developmental Biology 316 (2008) 302–311urogenital sinus epithelium, including the VMP, indicating that
buds grow outwards towards the Fgf10 source (Thomson and
Cunha, 1999). We propose that this is the initial phase of
development that is dependent on Fgf signalling and Sox9. The
second phase of development would then occur when the buds
have reached the Fgf10 source and start branching (Thomson
and Cunha, 1999; Timms et al., 1995).
Lobe specific identity within the prostate, reflected in the
specific structure and production of lobe specific secretory
proteins in the adult, is thought to be determined by regional
differences in the mesenchyme. This was established by tissue
recombination studies that showed that lobe identity within the
prostate epithelia was determined by the source of mesenchyme
within the recombinants (Hayashi et al., 1993; Kinbara et al.,
1996; Takeda et al., 1990; Timms et al., 1995). Therefore the
lobe specific phenotype in the Sox9 and Fgfr2 mutant animals
was puzzling as no difference in expression of these genes was
found between lobes as they formed and FGF10 mutant animals
showed a defect in development of all lobes. Our organ culture
studies at E17.5 with inhibitors of the Fgf signalling pathway
imply that there are lobe specific differences in their require-
ments for Fgf signalling for growth and differentiation. These
differences were found to be dependent on the stage of prostate
development. Therefore the timing of loss of gene function in
the Fgfr2 and Sox9 mutant mice, which is determined by the
timing of appearance of active Cre recombinase, relative to the
time course of prostate bud development could explain the lobe
specific phenotype in these mice.
Our model of Sox9 function implies that this factor is
essential for the development of the prostate at early stages of
bud formation but not at later stages, which explains the
presence of the anterior and dorso-lateral lobes in Sox9 mutant
animals. Although Sox9 is not required for the expression of
genes such as Nkx3.1 and Shh in the second phase of prostate
lobe development, it may have a role in the differentiation of
lobe structure. Consistent with this, the anterior prostate of Sox9
mutant animals shows a less elongated appearance than control
samples at E18.5 and an abnormal structure when grown under
the kidney capsule (Fig. 3D). However, due to the early lethality
of the Sox9 mutant embryos we were unable to determine
whether Sox9 had a role in processes such as branching
morphogenesis in the anterior and dorso-lateral lobes. One
possible explanation for the lack of a late phenotype in Sox9
mutant embryos is that the presence of other members of the
SoxE gene family, Sox8 and Sox10, could functionally
compensate for Sox9. This effect has been suggested in various
tissues including the gonad and neural crest cells (Chaboissier
et al., 2004; McCauley and Bronner-Fraser, 2006; Schepers
et al., 2003). However, we performed in situ hybridisation for
expression of these genes in the prostate and found no
evidence of expression in the developing prostatic buds (data
not shown).
A recent study by Wang et al. (2007) has reported the
presence of SOX9 in the basal cells of the adult human prostate
and in prostate cancer samples. Downregulation of SOX9 by
siRNA treatment showed a decrease in proliferation in prostate
cancer cells and a reduction in androgen receptor levels. Ourstudy showed that Sox9 regulates prostate epithelia proliferation
at specific stages in development and therefore our work might
inform the pathways implicated in the development of prostate
cancer.
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